|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date29 May 2019 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2IIT A randomized, double-blind, placebo-controlled Phase IIa exploratory proof-of-concept (PoC) clinical trial to evaluate the safety, tolerability, preliminary efficacy based on the modified Mayo score (mMayo), and pharmacokinetics of TAN-118 tablets in patients with active ulcerative colitis (UC) during a 4-week induction treatment.
/ Not yet recruitingPhase 2IIT A randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the safety, tolerability, preliminary efficacy based on the modified Mayo score, and pharmacokinetics/pharmacodynamics of multiple-dose 8-week induction treatment with TAN-118 tablets in patients with moderate to severe active ulcerative colitis.
评价TAN-118片在成人健康受试者中的单、多次给药的局部药代动力学的I期临床试验
[Translation] A Phase I clinical trial evaluating the local pharmacokinetics of TAN-118 tablets under single and multiple doses in healthy adult subjects.
定量分析单次与多次给药后TAN-118及其主要代谢物在不同结肠段组织中的浓度分布。
[Translation] Quantitative analysis was conducted on the concentration distribution of TAN-118 and its main metabolites in different colonic tissues after single and multiple administrations.
100 Clinical Results associated with Shanghai Thederma Pharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Shanghai Thederma Pharmaceuticals Co., Ltd.
100 Deals associated with Shanghai Thederma Pharmaceuticals Co., Ltd.
100 Translational Medicine associated with Shanghai Thederma Pharmaceuticals Co., Ltd.